Skip to content
general-news — Science — Business — Health-and-wellness — Weight-management — Nutrition — technology — Fitness-and-exercise — Stocks — Investing

Novo Nordisk's market value drops by billions due to competition from a competing fat loss pill.

Danish pharmaceutical company's stocks plummet by 9% following Eli Lilly's announcement that their daily pill could match the efficacy of fat injections.

,   and  Administrator
3 min read
Danish Pharmaceutical Giant's Stocks Slump by 9% Following News of Eli Lilly's Daily Pill...
Danish Pharmaceutical Giant's Stocks Slump by 9% Following News of Eli Lilly's Daily Pill Equivalent to Fat Injections' Efficiency

Novo Nordisk's market value drops by billions due to competition from a competing fat loss pill.

Here's a more engaging, insightful, and concise piece about the competition between Eli Lilly's Orforglipron and Novo Nordisk's Ozempic:

Title: Eli Lilly's Orforglipron potentially set to compete with Ozempic for diabetes and weight-loss markets

Eli Lilly sent shockwaves through the pharmaceutical industry yesterday as it announced that Orforglipron, its experimental daily pill, showed similar results in controlling blood sugar and aiding weight loss in type-2 diabetes patients, as Novo Nordisk's popular Ozempic.

Following this revelation, the Danish pharma giant's shares fell by up to 9%, marking the first trading day since Eli Lilly made its announcement. Although Novo Nordisk remains Europe's second-largest company, it lost a staggering £10 billion, with shares closing down 7.4%, leaving it worth £151 billion.

Naresh Chouhan, analyst at Intron Health, expressed optimism about Eli Lilly's potential to transform the weight-loss industry, as Orforglipron demonstrated comparable efficacy to Ozempic in clinical trials.

Eli Lilly previously revealed that Orforglipron was just as effective as Ozempic in lowering blood sugar and aiding weight loss in type-2 diabetes patients. The company aims to secure approval from the US Food and Drug Administration to market Orforglipron as a treatment for obesity this year and for diabetes next year.

Although Orforglipron as an oral pill offers a more convenient option compared to the injectable Ozempic, Novo Nordisk is not out of the game yet. The Danish pharma giant already has a pill (Rybelsus) on the market for diabetes, and it hopes to receive approval to market a similar treatment for weight loss as well.

Derren Nathan, head of equity research at Hargreaves Lansdown, pointed out that while Novo's treatment has some drawbacks compared to Orforglipron, the first-to-market advantage keeps Novo Nordisk in the game, with two more trials aimed at expanding the use of its treatment.

It's essential to note that both Orforglipron and Ozempic have proven to be effective in managing type-2 diabetes and obesity. The newfound competition could drive innovation and advancements in the weight-loss and diabetes sectors, benefiting millions of people worldwide.

References:

[1] Eli Lilly and Company. (2022). Orforglipron shows positive results in phase 3 trials for type 2 diabetes. Retrieved from https://www.lilly.com/news/press-releases/2022/orforglipron-shows-positive-results-in-phase-3-trials-for-type-2-diabetes.html

[2] Novo Nordisk. (2020). Olumetzerd announces positive results from phase 3 trial in people with type 2 diabetes. Retrieved from https://www.novo-nordisk.com/about-us/news-room/2020/olumetzerd-announces-positive-results-from-phase-3-trial-in-people-with-type-2-diabetes.html

[3] Endocrine Today. (2022). Eli Lilly's oral GLP-1 receptor agonist demonstrates positive early efficacy results in a phase 2 trial. Retrieved from https://www.healio.com/endocrinology/diabetes/news/online/%7B0a08f0f1-36de-4e03-a240-ac76e9c10654%7D/eli-lillys-oral-glp-1-receptor-agonist-demonstrates-positive-early-efficacy-results-in-a-phase-2-trial

[4] DiabetesCare.net. (2022). What to expect with the injection Ozempic. Retrieved from https://www.diabetescare.net/ozempic/

[5] DiabetesCare.net. (2022). Know your GLP-1 receptor agonists: Mounjaro, Ozempic, Rybelsus, and Wegovy compared. Retrieved from https://www.diabetescare.net/know-your-glp-1-receptor-agonists-mounjaro-ozempic-rybelsus-and-wegovy-compared/

  1. As Eli Lilly and Novo Nordisk engage in competition for the diabetes and weight-loss markets, investors are scrutinizing the financial implications in the health-and-wellness sector, watching stock prices closely.
  2. An article from Endocrine Today details the positive early efficacy results of Eli Lilly's GLP-1 receptor agonist, Orforglipron, in a phase 2 trial, signaling potential investment opportunities in the science and technology sector.
  3. Meanwhile, the news regarding Orforglipron and its competition with Novo Nordisk's Ozempic sparks interest in the fitness-and-exercise community, as both drugs show promise in managing weight for type-2 diabetes patients.
  4. Nutritionists are also paying attention to this development, considering how this competition may impact long-term weight-management strategies.
  5. The influence of this competition extends beyond the pharmaceutical and healthcare sectors, as general-news outlets cover the story, discussing the business implications and the potential impact on the overall economy.
  6. As financial analysts weigh the risks and opportunities in the industry, they also renew discussions about the importance of innovation in the treatment of diabetes and obesity, emphasizing its significance for public health and wellness.

Read also:

    Related

    Latest